
|Articles|July 1, 2005
Oracea phase 3 clinical trials show 'highly significant' results
Newtown, Pa. — CollaGenex Pharmaceuticals announces the "highly significant" positive outcomes of two phase 3, double-blinded, placebo-controlled clinical trials designed to evaluate the safety and efficacy of Oracea for the treatment of rosacea.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
CSU With Biochemical C1 Inhibitor Deficiency: Case Report Raises Diagnostic Questions
3
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
4
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
5











